BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guedes JVM, Aquino JA, Castro TLB, Augusto de Morais F, Baldoni AO, Belo VS, Otoni A. Omeprazole use and risk of chronic kidney disease evolution. PLoS One 2020;15:e0229344. [PMID: 32130255 DOI: 10.1371/journal.pone.0229344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Meyer JC, Macbride-stewart S, Fadare JO, Abdulrahman Jairoun A, Haque M, Massele A, Kumar S, Sefah IA, P Skosana P, Godman B. Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. Cureus 2022. [DOI: 10.7759/cureus.31918] [Reference Citation Analysis]
2 Lien H, Wang Y, Huang M, Wu H, Huang C, Chen C, Hung S, Chen C, Chiu C, Lai C. Gastroprotective Effect of Anisomeles indica on Aspirin-Induced Gastric Ulcer in Mice. Antioxidants 2022;11:2327. [DOI: 10.3390/antiox11122327] [Reference Citation Analysis]
3 Zhao Y, Sun C, Su M, Shi J, Hu Z, Peng Y, Zheng J. Evidence for Metabolic Activation of Omeprazole In Vitro and In Vivo. Chem Res Toxicol 2022. [PMID: 35994611 DOI: 10.1021/acs.chemrestox.2c00111] [Reference Citation Analysis]
4 Mansi IA, Chansard M, Lingvay I, Zhang S, Halm EA, Alvarez CA. Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study. PLoS ONE 2022;17:e0269982. [DOI: 10.1371/journal.pone.0269982] [Reference Citation Analysis]
5 Wei X, Yu J, Xu Z, Wang C, Wu Y. Incidence, Pathogenesis, and Management of Proton Pump Inhibitor-Induced Nephrotoxicity. Drug Saf 2022. [PMID: 35641849 DOI: 10.1007/s40264-022-01181-4] [Reference Citation Analysis]
6 Laquière A, Trottier-tellier F, Urena-campos R, Lienne P, Lecomte L, Katsogiannou M, Penaranda G, Boustière C, Nakamura M. Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study. Gastroenterology Research and Practice 2022;2022:1-6. [DOI: 10.1155/2022/1606944] [Reference Citation Analysis]
7 Rajan P, Iglay K, Rhodes T, Girman CJ, Bennett D, Kalantar-zadeh K. Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review. Therap Adv Gastroenterol 2022;15:175628482210741. [DOI: 10.1177/17562848221074183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wakabayashi T, Hosohata K, Oyama S, Inada A, Niinomi I, Kambara H, Iida T, Hasebe K, Matsuoka H, Uchida M, Kumagai E. Association between a low dose of proton pump inhibitors and kidney function decline in elderly hypertensive patients: a retrospective observational study. J Int Med Res 2021;49:3000605211006653. [PMID: 33845606 DOI: 10.1177/03000605211006653] [Reference Citation Analysis]
9 Omeprazole. Reactions Weekly 2020;1803:190-190. [DOI: 10.1007/s40278-020-78384-0] [Reference Citation Analysis]